Safety and Efficacy of AGN-INM176 in Prostate Patients With Rising PSA

Summary

This Phase I/II open-label trial aims to evaluate the safety and efficacy of the herbal supplement INM176 in patients with a history of prostate cancer or low-risk disease under active surveillance. The study will determine the recommended Phase II dose (RP2D) and assess the efficacy of INM176 in stabilizing or decreasing plasma PSA levels in post-radical prostatectomy (RP) and post-radiation therapy (RT) patients with rising PSA levels.

Timeline

Start

2025-05-07

Primary completion

2027-05-01

Completion

2028-05-01

Drugs

Indications